Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enact Holdings Inc (ACT) vs Biogen Inc (BIIB) Price & Performance

Enact Holdings IncTrade
Biogen IncTrade

Price performance (Past 24H)

Key statistics

Enact Holdings Inc vs Biogen Inc — how do they compare? Enact Holdings Inc trades at $49.46 (market cap $6.75B), while Biogen Inc trades at $206.48 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 4.5× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.

ACTBIIB
Market Cap
$6.75B$30.13B
Sector
TechnologyHealth
52-Week High
$49.12$216.63
52-Week Low
$34.93$128.93
Enterprise Value
$7.05B$37.20B
Dividend Yield
1.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enact Holdings Inc

ACT trades at $49.47, up 2.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong profitability with a net income margin of 54.5% and ROE of 12.9%, supported by recent earnings beats. Revenue growth is modest, and the company maintains a consistent dividend policy. Analyst consensus is a $49.00 price target with a mix of buy and hold ratings.

Outlook is stable with solid fundamentals, but high valuation multiples and overbought technicals suggest limited near-term upside. Risks include reliance on earnings consistency and market sentiment shifts. The stock offers value through dividends and profitability, yet investors should weigh current levels against growth prospects.

Biogen Inc

Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.

The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.

Returns comparison

Trailing returns across standard periods

About Enact Holdings Inc

Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.

Read more on ACT

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB